1. A Prognostic Gene-Expression Signature and Risk Score for Meningioma Recurrence After Resection.
- Author
-
Chen, William C, Vasudevan, Harish N, Choudhury, Abrar, Pekmezci, Melike, Lucas, Calixto-Hope G, Phillips, Joanna, Magill, Stephen T, Susko, Matthew S, Braunstein, Steve E, Oberheim Bush, Nancy Ann, Boreta, Lauren, Nakamura, Jean L, Villanueva-Meyer, Javier E, Sneed, Penny K, Perry, Arie, McDermott, Michael W, Solomon, David A, Theodosopoulos, Philip V, and Raleigh, David R
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Research ,Genetics ,Human Genome ,Biotechnology ,Rare Diseases ,Genetic Testing ,4.1 Discovery and preclinical testing of markers and technologies ,Good Health and Well Being ,Adult ,Aged ,Cohort Studies ,Female ,Humans ,Male ,Meningeal Neoplasms ,Meningioma ,Middle Aged ,Multivariate Analysis ,Neoplasm Recurrence ,Local ,Neurosurgical Procedures ,Prognosis ,Retrospective Studies ,Risk Factors ,Transcriptome ,Biomarker ,Gene expression ,Prognostic ,WHO grade ,Recurrence ,Survival ,Resection ,Radiation ,Expression ,Gene ,WHOgrade ,Neurosciences ,Neurology & Neurosurgery ,Clinical sciences ,Biological psychology - Abstract
BackgroundPrognostic markers for meningioma are needed to risk-stratify patients and guide postoperative surveillance and adjuvant therapy.ObjectiveTo identify a prognostic gene signature for meningioma recurrence and mortality after resection using targeted gene-expression analysis.MethodsTargeted gene-expression analysis was used to interrogate a discovery cohort of 96 meningiomas and an independent validation cohort of 56 meningiomas with comprehensive clinical follow-up data from separate institutions. Bioinformatic analysis was used to identify prognostic genes and generate a gene-signature risk score between 0 and 1 for local recurrence.ResultsWe identified a 36-gene signature of meningioma recurrence after resection that achieved an area under the curve of 0.86 in identifying tumors at risk for adverse clinical outcomes. The gene-signature risk score compared favorably to World Health Organization (WHO) grade in stratifying cases by local freedom from recurrence (LFFR, P
- Published
- 2021